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Aims. To develop a fast and robust DNA-based assay to detect insertions and deletions mutations in exon 34 that encodes the
PEST domain of NOTCH1 in order to evaluate patients with chronic lymphocytic leukemia (CLL). Methods. We designed a
multiplexed allele-specific polymerase chain reaction (PCR) combined with a fragment analysis assay to detect specifically the
mutation c.7544 7545delCT and possibly other insertions and deletions in exon 34 of NOTCH1. Results.We evaluated our assay in
peripheral blood samples from two cohorts of patients with CLL.The frequency ofNOTCH1mutations was 8.4% in the first cohort
of 71 unselected CLL patients. We then evaluated a second cohort of 26 CLL patients with known cytogenetic abnormalities that
were enriched for patients with trisomy 12.NOTCH1mutations were detected in 43.7% of the patients with trisomy 12. Conclusions.
We have developed a fast and robust assay combining allele-specific PCR and fragment analysis able to detect NOTCH1 PEST
domain insertions and deletions.
1. Introduction
Chronic lymphocytic leukemia (CLL) is a neoplastic disorder
of B lymphocytes characterized by progressive increase in
CD5+ B cells in the peripheral blood (PB), bone marrow,
and lymph nodes. The clinical course of CLL is highly
heterogeneous, with some patients experiencing indolent
disease, with no treatment requirement for several years,
and others showing aggressive course and decreased overall
survival (OS) [1].
Although several prognostic factors have been identified
in CLL, such as TP53 mutation, cytogenetic abnormalities,
IGVH mutational status, the only biomarkers utilized to
inform clinical decisions nowadays are 17p orTP53mutations
[1]. Since these alterations are present in a minority of
patients, most CLL cases are treated based on clinical criteria.
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Recently, novel prognostic relevant recurrent mutations
in genes such as NOTCH1, SF3B1, and BIRC3 have been
identified inCLL [2, 3].Themost commonof these alterations
are NOTCH1 and SF3B1 mutations, which are present in
around 10% of CLL patients at diagnosis [2].
NOTCH1 mutations in CLL occur almost exclusively
in the genic region encoding the PEST domain and are
characterized by frameshift insertions and deletions, with
the mutation c.7544 7545delCT representing more than 75%
of the mutations [4, 5]. In addition, NOTCH1 mutations
have been associated with decreased OS and treatment-free
survival (TFS) in several independent studies [3–6].The goal
of thisworkwas to develop a simple, robust, and cost-effective
assay to identify NOTCH1 PEST domain mutations and also
to evaluate the frequency of NOTCH1 mutations in a cohort
of CLL patients.
2. Methods
This study was approved by the Institutional Review Board of
Hospital Israelita Albert Einstein (protocol 1699-13). Consent
form was waived, since the samples were deidentified and
the researchers did not have access to clinical information.
Peripheral bloodmononuclear cells were isolated (PBMC) by
Ficoll-Paque gradient centrifugation and genomic DNA was
extracted with QIAamp DNA Mini Kit (Qiagen). Fragment
analysis and sequencing with BigDye Terminator v3.1 Cycle
Sequencing Kit were performed in the equipment 3500XL
Genetic Analyzer (Applied Biosystems).
Polymerase chain reaction (PCR) amplification and
sequence analysis of IGHV-D-J rearrangements were per-
formed on genomic DNA from PB samples, using VH frame-
work region 1 (FR1) consensus family specific primers (VH1–
VH6) and a JH primer, according to the BIOMED-2 protocol
[7]. When amplification was unsuccessful, an alternative set
of primers that anneal to the leader region (LH1–LH6) and
a JH consensus primer were used. Clonal PCR products
were purified using Wizard SV Gel and PCR Clean-Up
System (Promega), and both strands were directly sequenced
with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Carlsbad, CA) on a 3130XL Genetic Analyzer
(Applied Biosystems).The sequenceswere aligned to the clos-
estmatching germ line gene by using IMGT’sV-QUEST anal-
ysis tool (http://www.imgt.org/IMGT vquest/ share/textes/)
and NCBI’s IgBLAST tool (https://www.ncbi.nlm.nih.gov/
igblast/). Sequences with a germ line identity greater than or
equal to 98% were considered unmutated and those with an
identity less than 98% were considered mutated [8].
Exact Fisher’s test was used to compare patients with
mutated andwild-typeNOTCH1 regarding IGVHmutational
status.
3. Results
The assay we developed had two main goals: to detect
insertions and deletions in the region of NOTCH1 exon 34
encoding the PEST domain and also to specifically detect the
mutation c.7544 7545delCT, which accounts for around 80%
of all NOTCH1 mutations in CLL [4]. To accomplish this,
we designed a fragment analysis PCR with three primers: a
forward primer (N1F) labeled with FAM (CATCCAGCA-
GCAGCAAAGC), a nonspecific reverse primer (NWR)
(GTCGGAGACGTTGGAATGC) that amplifies the wild-
type sequence, and another allele-specific reverse primer
that amplifies only the mutation c.7544 7545delCT (NMR)
(CCACTGGTCAGGGGACTCG). We then performed a
single PCR reaction with the three primers. Samples with
wild-typeNOTCH1would produce a single product of 391 bp;
samples harboring heterozygous c.7544 7545delCT would
generate three products: 391 bp (wild-type allele), 389 bp
(amplification of the mutated allele with primers N1F and
NWR), and 356 bp (amplification of the mutated allele with
N1F and NMR) (Figures 1(a) and 1(b)). Finally, samples
with another heterozygous insertion or deletion in the PEST
domain would yield two products, 391 bp from the wild-type
allele and another variable product, depending on the size of
the insertion or deletion.
To validate our assay, we evaluated two groups of CLL
patients. The initial group consisted of consecutive dei-
dentified samples from 71 patients with CLL in distinct
disease stages that had PB flow cytometry evaluation at
our laboratory, for which we had no clinical or cytogenetic
information. We identified NOTCH1mutations in 6 patients
(8.4%). To confirm that our test was indeed detecting the
expectedmutations, we performed Sanger sequencing of all 6
positive cases and 3 negative cases, confirming the specificity
of our assay (Figure 1(c)).
We then analyzed a second group of 26 consecutive CLL
patients that had been successfully evaluated with fluorescent
in situ hybridization (FISH) at our laboratory. All these
patients had recurrent cytogenetic abnormalities (trisomy 12,
13q, 17p, and 11q present in 16, 6, 3, and 1 patient, resp.).
This group was enriched for patients with trisomy 12, since
this population is known to harbor NOTCH1 mutations
frequently [9]. We found NOTCH1 mutations in 10 patients
of the second cohort (38.4%). Among patients with trisomy
12 (𝑛 = 16), the prevalence of NOTCH1mutations was 43.7%
(𝑛 = 7), in agreementwith previous reports [9]. Allmutations
identified in these patients (𝑛 = 16) were c.7544 7545delCT.
We did not find other NOTCH1 mutations in CLL patients.
While 15 patients had heterozygous mutation, 1 patient
presented with a homozygous mutation.
Since the presence of NOTCH1 mutations has been
associated with unmutated IGVH [5], we performed IGVH
mutational status analysis in 63 out of the 97 analyzed
patients, based on DNA availability. Among these samples,
9 had NOTCH1 mutation and 54 had wild-type NOTCH1.
IGVH mutational status was inconclusive in 10 patients due
to low numbers of CLL cells in PB. Among the 53 evaluable
patients, unmutated IGVH was detected in 100% ofNOTCH1
mutated cases (𝑛 = 7) and in 37% (𝑛 = 17) of patients
with wild-type NOTCH1 (𝑝 = 0.002), confirming previous
findings [10].
We next determined the sensitivity of our test with
serial dilutions of the cell line MOLT4 which carries a
heterozygous c.7544 7545delCT NOTCH1 mutation, using
normal peripheral blood mononuclear cells. We diluted
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Figure 1: Fragment analysis and sequencing results. (a) Fragment analysis of a sample with wild-type NOTCH1 revealing a single 391 bp peak.
(b) Fragment analysis of a chronic lymphocytic leukemia (CLL) sample harboring the NOTCH1 PEST domain mutation c.7544 7545delCT
showing three distinct peaks: a 391 bp peak, corresponding to wild-type NOTCH1, a 389 bp peak, amplified with primers N1F and NWR
(non-mutation-specific), revealing a 2 bp deletion, and a 356 bp peak, amplified with the allele-specific primer NMR. (c) Sanger sequencing
of a sample carrying the NOTCH1 mutation c.7544 7545delCT (upper panel) and a wild-type sample (lower panel).
320 340 360 380 400 420 440 460
28000
24000
20000
16000
12000
8000
4000
0
(a)
320 340 360 380 400 420 440 460
28000
24000
20000
16000
12000
8000
4000
0
(b)
320 340 360 380 400 420 440 460
28000
24000
20000
16000
12000
8000
4000
0
(c)
320 340 360 380 400 420 440 460
28000
24000
20000
16000
12000
8000
4000
0
(d)
Figure 2: Fragment analysis of 4 samples not harboring the mutation c.7544 7545delCT. (a) Sample with wild-type NOTCH1 revealing
a single 391 bp peak. (b) T-ALL140 sample harboring the mutation c.7526 7527insT, showing a 391 bp peak and a 392 bp peak. (c) T-ALL151
samplewith the complexmutation c.7458 7464delGCAGCAC, c.7457 7458insAGGCGTCTAGCCGCAT, revealing a 391 bp peak and a 400 bp
peak. (d) T-ALL176 sample with the mutation c.7529 7535delTCACCCC, depicting a 391 bp peak and a 384 bp peak.
samples in the following way: 1 : 2, 1 : 5, 1 : 10, 1 : 20, and 1 : 40.
The sensitivity of our test was 5%, meaning we can detect
NOTCH1 mutations when 5% of cells harboring NOTCH1
heterozygous mutations are mixed with 95% of cells with
wild-type NOTCH1.
In order to calculate the sensitivity of our assay to other
exon 34 NOTCH1 insertions and deletions, given that the
only mutation detected in CLL patients in our study was
c.7544 7545delCT, we evaluated three samples from patients
with T-acute lymphoblastic leukemia (T-ALL), known to
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harbor insertions and deletions inNOTCH1 exon 34. Our test
correctly identified all three mutations in these samples (see
Figure 2).
4. Discussion
Mutated NOTCH1 is a biomarker associated with Richter
transformation, chemoresistance, and reduced overall and
progression-free survival in CLL [10, 11]. These mutations
are characterized by frameshift insertions and deletions in
exon 34, with c.7544 7545delCT occurring in around 80%
of mutated cases [4, 10]. The functional consequence of such
NOTCH1mutations is the disruption of the PESTdomain and
stabilization of the NOTCH1 protein leading to constitutive
activation of NOTCH1 pathway [12]. For these reasons, the
evaluation of NOTCH1 mutational status may have implica-
tions for the clinical management of CLL patients. We have
thus developed a fast, robust, and sensitive assay for detection
of NOTCH1 PEST domain insertions and deletions.
Our data is consistent with previous findings of around
10% prevalence of NOTCH1 mutations in unselected CLL
patients and around 40% prevalence in CLL with trisomy
12 [6, 9]. Of note, mutations in the gene FBXW7, which
belongs to NOTCH1 pathway, also seem to bemore prevalent
in patients with trisomy 12 and are associated with a worse
outcome [13]. In addition, the previously described high cor-
relation between unmutated IGVH and NOTCH1 mutations
was confirmed in our cohort [4, 10].
The identification of NOTCH1 mutations in CLL can be
useful as a prognostic marker [4] and also as a potential
therapeutic target in the future [14]. The analysis of NOTCH1
mutations in patients from the German CLL8 trial sug-
gests that CLL patients harboring NOTCH1 mutations may
not benefit from the addition of rituximab to fludarabine
and cyclophosphamide, indicating that NOTCH1 may also
become a predictive marker of response to rituximab in CLL
[15].
While our test was developed to detect any insertions and
deletions in exon 34, in our CLL cohort, we only identified
the most common deletion, c.7544 7545delCT, in agreement
with previous findings [3, 7]. Nevertheless, the identification
of other insertions and deletions in T-ALL samples validates
our assay to other mutations that are rarer and may be
found in CLL (see Figure 2). Our assay does not detect
single nucleotide variations that may be found on NOTCH1
exon 34; nevertheless, the pathogenic significance of such
mutations remains to be defined [16].
In conclusion, we have developed a simple and robust
assay combining allele-specific PCRand fragment analysis for
the identification of NOTCH1 PEST domain mutations. We
have also shown that, among Brazilian patients analyzed, the
prevalence of NOTCH1 mutations and the correlation with
unmutated IGVH in CLL are in agreement with previous
reports [3–6].
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